SCHEMBL4635836

SCHEMBL4635836

N#Cc1ccc(N2CC3C(N)C3C2)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
AR P10275 17/20 0.58
DPP4 P27487 1/20 0.47
PREP P48147 1/20 0.47
DPP8 Q6V1X1 1/20 0.47
DPP9 Q86TI2 1/20 0.47
DPP7 Q9UHL4 1/20 0.47
TRPV4 Q9HBA0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635204 0.82 DPP4 (0.47) ARDPP4PREPDPP8DPP9
SCHEMBL22210521 0.81 AR (0.54) ARDPP4PREPDPP8DPP9
SCHEMBL22209791 0.81 AR (0.54) ARDPP4PREPDPP8DPP9
SCHEMBL13651246 0.81 AR (0.72) ARDPP4PREPDPP8DPP9
SCHEMBL13651244 0.81 AR (0.72) ARDPP4PREPDPP8DPP9
SCHEMBL4635278 0.78 AR (0.54) ARDPP4
Hydrochloric Acid SCHEMBL30994859 0.78 AR (0.60) ARDPP4PREPDPP8DPP9
SCHEMBL4299688 0.76 AR (0.61) ARTRPV4
SCHEMBL15117196 0.74 AR (0.60) ARTRPV4
SCHEMBL10063487 0.74 AR (0.60) ARTRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 AR 1279/4885DPP4 1/4885PREP 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.